United Therapeutics Corporation (UTHR)

Several events have impacted United Therapeutics' stock price in the past six months. The company announced a $1 billion Accelerated Share Repurchase (ASR) program in August 2025. In September 2025, the company's stock surged by 33% following positive late-stage clinical trial results for Tyvaso in idiopathic pulmonary fibrosis (IPF). For Q3 2025, United Therapeutics reported earnings per share (EPS) that exceeded analyst expectations. In January 2026, the company announced positive results from a Phase 1 study of miroliverELAP® in patients with acute liver failure, and Kevin J. Tracey was appointed to the company's Board of Directors. There has been notable insider selling in the last three months. Analysts generally maintain a positive outlook, with a consensus rating of "Moderate Buy" to "Buy".

Specific detailed information regarding the demand seasonality for United Therapeutics' products and services is not readily available. However, the company's focus on chronic and life-threatening diseases suggests that demand for its core therapeutic products may be relatively stable and less subject to significant seasonal fluctuations. The company's revenue has shown consistent growth year-over-year.

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing products for chronic and life-threatening diseases, particularly rare diseases and organ manufacturing. The company's major products target pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), including Tyvaso DPI, Tyvaso Inhalation Solution, Remodulin Injection, Orenitram Extended-Release Tablets, Adcirca Tablets, and Unituxin Injection. United Therapeutics is also developing biopharmaceutical medicinal products such as manufactured organs for transplantation through xenotransplantation, allogenic recellularization, and autologous bioprinting technologies.

United Therapeutics is co-headquartered in Silver Spring, Maryland, and Research Triangle Park, North Carolina, with additional facilities in other U.S. states and Canada. The company's products are sold in the U.S. and Canada, and are also available in Central and South America, Europe, the Middle East, and Asia through various distribution partners. The majority of the company's revenue is generated from the United States.

United Therapeutics maintains a strong brand reputation, driven by its mission to develop treatments for rare, deadly diseases and its pioneering work in organ manufacturing. The company operates as a public benefit corporation (PBC), balancing shareholder interests with its public benefit purpose. Positive clinical trial results, such as those for Tyvaso in IPF and the miroliverELAP® bioengineered liver, further enhance its reputation. The company faces ongoing litigation with Liquidia Technologies regarding competition for its Tyvaso product.

Institutional investors hold a significant portion of United Therapeutics' stock, with approximately 84.75% to 94.08% institutional ownership. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc, Renaissance Technologies Llc, Avoro Capital Advisors LLC, and State Street Corp. Insiders own about 7.09% to 10.3% of the company's stock. Individual investors and public companies hold the remaining shares.